(SWX:WIHN),(NASDAQ:WKEY),(NASDAQ:LAES), WISeKey to ConnectWISeRobot.CH to the WISeSat.Space Constellation protected by SEALSQ Post-Quantum Cryptography; The Robot PoC will be showcased at WISeKEY's CEO Carlos Moreira's next public appearance in France at Tech & Fest Video link is available at https://youtube.com/shorts/XsVQlcDtfTQ Geneva, Switzerland — February 3, 2026 -WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a […]

(Euronext Amsterdam:PHARM),(NasdaqGM:PHARM),(Euronext Amsterdam:PHARM), Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease Introduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program 2026 total revenue guidance of US$405 – US$425 million (8% to 13% growth) 2026 total operating expense guidance of

(Paris:SAN), Sanofi announces the signing of a share buyback mandate for up to EUR1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of EUR1 billion. On February 2, 2026, Sanofi entered a mandate with an investment service provider for this program. Under

(Paris:VLA),(Paris:VLAP), Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research centers, today announced the initiation of a Pilot Vaccination Strategy (PVS) in Brazil using Valneva's single-shot chikungunya vaccine, IXCHIQ(R). The pilot vaccination program will serve

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment GlobeNewswire February 03, 2026 Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused

WISeKey to ConnectWISeRobot.CH to the WISeSat.Space Constellation protected by SEALSQ Post-Quantum Cryptography; GlobeNewswire February 03, 2026 WISeKey to ConnectWISeRobot.CH to the WISeSat.Space Constellation protected by SEALSQ Post-Quantum Cryptography; The Robot PoC will be showcased at WISeKEY's CEO Carlos Moreira's next public appearance in France at Tech & Fest Video link is available at https://youtube.com/shorts/XsVQlcDtfTQ Geneva,

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day GlobeNewswire February 03, 2026 Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial disease Introduces napazimone (KL1333) as the compound name for the mtDNA-driven mitochondrial disease program 2026 total revenue guidance

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ(R) GlobeNewswire February 03, 2026 Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research centers, today announced the

Press Release: Sanofi announces the signing of a share buyback mandate for up to EUR1 billion GlobeNewswire February 03, 2026 Sanofi announces the signing of a share buyback mandate for up to EUR1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to execute a share buyback program in 2026 of

Creatine has long been a staple supplement for athletes and active individuals, but traditional formats such as powders, capsules, and tablets often come with trade-offs related to taste, preparation, and convenience. In response to these limitations, Natures Aid has introduced a gummy-based creatine supplement designed to combine verified formulation standards with a more accessible and